Prior to founding Elephas in 2020, Maneesh was CEO of Farcast Biosciences, a venture-backed cancer diagnostics company focused on improving treatment outcomes for cancer patients. Before joining Farcast, Maneesh served as Chief Operating Officer of Exact Sciences Corporation for ten years where he helped lead the growth of the company from 3 employees to over 3,000 at the end of his tenure there. Exact Sciences’ focus is the early detection and prevention of colon cancer. Exact’s lead product, Cologuard, was developed in collaboration with Mayo Clinic and is now widely available in the US as a front-line screening method for colorectal cancer, reimbursed by both Medicare and all major insurers. Prior to joining Exact, Maneesh worked for Third Wave Technologies, Inc., a molecular diagnostics company, from 2003 until its acquisition by Hologic, Inc. in July 2008. Third Wave Technologies developed an HPV product for cervical cancer screening. During his time at Third Wave, he was responsible for business strategy and commercial operations before being promoted to Chief Financial Officer in January 2006. Maneesh earned a BA in economics from the University of Chicago and an MBA from the Kellogg School of Management at Northwestern University.

Steven K. Galson, MD, MPH, is a consultant to Amgen and serves on the Board of Directors of Insilico Medicine and Biocryst Pharmaceuticals. Until June 2020 he was a senior vice president of Research and Development at Amgen. He joined the company in 2010 as vice president of Global Regulatory Affairs. Prior to Amgen, Dr. Galson was senior vice president for Civilian Health Operations and chief health scientist at Science Applications International Corporation.

Dr. Galson spent more than 20 years in government service, including two years as acting Surgeon General of the United States. Previously, he served as director of the FDA’s Center for Drug Evaluation and Research (CDER), where he provided leadership for the center’s broad national and international programs in pharmaceutical regulation.

Dr. Galson began his public health service career as an epidemiological investigator at the Centers for Disease Control and Prevention (CDC) after completing a residency in internal medicine at the Hospitals of the Medical College of Pennsylvania. He also held senior-level positions at the Environmental Protection Agency; the Department of Energy, where he was chief medical officer; and the Department of Health and Human Services.

Paul Berns joined ARCH in 2018 as a Venture Partner and moved into a Managing Director role in 2021. He is Chairman of the board of directors of Neumora Therapeutics, Happy AI, Epirium Bio, and HI Bio. Additionally, Mr. Berns is a board member of Unity Biotechnology (UBX) and EQRx. Mr. Berns previously served on the boards of Jazz Pharmaceuticals, PLC, MC2 Therapeutics, Menlo Therapeutics, Anacor Pharmaceuticals, XenoPort, Allos Therapeutics, and Bone Care International. Mr. Berns is also the Founder and Chief Executive Officer of Neumora Therapeutics, and served as President, Chief Executive Officer and Chairman of the board of directors at Anacor Pharmaceuticals from 2014 until its acquisition by Pfizer, Inc. in 2016. Mr. Berns served as President and Chief Executive Officer of Allos Therapeutics, Inc., a biotechnology company, from 2006 to 2012 when it was acquired by Spectrum Pharmaceuticals and was the President and Chief Executive Officer of Bone Care International, Inc., a specialty pharmaceutical company, from 2002 to 2005 when it was acquired by Genzyme Corporation.

Mr. Berns was a consultant to the pharmaceutical industry from July 2016 to August 2018, as well as from August 2012 to March 2014 and from July 2005 to March 2006. Prior to that, Mr. Berns was Vice President and General Manager of the Immunology, Oncology and Pain Therapeutics business unit of Abbott Laboratories from 2001 to 2002, and from 2000 to 2001, he served as Vice President, Marketing of BASF Pharmaceuticals/Knoll, when it was acquired by Abbott Laboratories in 2001. Earlier in his career, Mr. Berns held various positions, including senior management roles, at Bristol Myers Squibb (BMS) from 1990 to 2000.

Mr. Berns received his B.S. in Economics from the University of Wisconsin.